Skip to main
LUCD
LUCD logo

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. reported an 8% year-over-year growth in EsoGuard test volume during 3Q24, reaching 2,787 tests. The company anticipates improved revenue growth as it processes claims and collects payments, with expectations for accelerated volume growth following increased market coverage from Medicare and other insurers. Additionally, positive results from the ENVET-BE clinical utility study, which highlighted a significant increase in Barrett's esophagus diagnostic yield for EsoGuard, bolster the outlook for rapid revenue growth as the company continues to commercialize its products.

Bears say

Lucid Diagnostics Inc. is facing a deteriorating financial outlook as test volumes experienced a sequential decline of approximately 11%, despite an 8% year-over-year increase, indicating issues with sustained growth and market penetration. Additionally, the company has revised its revenue estimates for 2024 and 2025 downward, reflecting a lack of confidence in future performance amid increasing operating losses, which grew to $11.7 million in the most recent quarter. The prospects for the company's products, EsoGuard and EsoCheck, remain uncertain due to potential obstacles such as slow adoption rates, insurance reimbursement issues, ineffective marketing strategies, and competition from other cancer detection tests.

Lucid Diagnostics (LUCD) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.